[Determining cardiovascular risk in patients with rheumatoid arthritis: waiting for trial outcomes is not...

Area of Science:

• Rheumatology and Cardiology
• Inflammatory Diseases and Cardiovascular Health

Context:

• Patients with rheumatoid arthritis (RA) exhibit a cardiovascular disease (CVD) risk comparable to individuals with diabetes.
• Established CVD risk management strategies are crucial for RA patients, despite a lack of specific large-scale clinical endpoint trials.

Purpose:

• To emphasize the critical need for cardiovascular risk management in rheumatoid arthritis patients.
• To advocate for the use of anti-inflammatory therapies, statins, and antihypertensives in RA management.
• To highlight the comparable efficacy of these treatments in RA patients versus the general population.

Summary:

• Cardiovascular risk in RA patients is significant, necessitating proactive management.
• Treatments like statins and antihypertensives are presumed effective in RA, mirroring their general population benefits.
• Comprehensive management includes suppressing chronic inflammation and indicated pharmacological interventions.

Impact:

• Recommends universal cardiovascular risk management for all RA patients.
• Suggests that current evidence supports the use of statins and antihypertensives in RA.
• Underscores the importance of clinical monitoring to validate treatment efficacy in reducing CVD events in RA.